Protocol detail

Phase 3 Trial of Platinum-Sensitive Recurrent Ovarian Cancer

Protocol full text hidden due to copyright restrictions

However, the full text is available at the following link: Access Free Full Text.

Coleman R.L., Oza A.M., Lorusso D., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J.I., Clamp A., Scambia G., Leary A., Holloway R.W., Gancedo M.A., Fong P.C., Goh J.C., O’Malley D.M., Armstrong D.K., Garcia-Donas J., Swisher E.M., Floquet A., Konecny G.E., McNeish I.A., Scott C.L., Cameron T., Maloney L., Isaacson J., Goble S., Grace C., Harding T.C., Raponi M., Sun J., Lin K.K., Giordano H, & Ledermann J.A. (2017). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 390(10106), 1949-1961.

Publication 2017

Bevacizumab Bulky Cancer Cancer antigen 125 Central nervous system Chemotherapy Conference Disease progression Endometrioid Fallopian tube carcinoma Hospitals patients Institutional review boards Metastases Oncology Ovarian Parp inhibitor Patients Peritoneal Placebo Platinum Radiological Regimen Residual carcinoma Residual disease Serous

Corresponding Organization : The University of Texas MD Anderson Cancer Center

Other organizations : University Health Network, Princess Margaret Cancer Centre, Fondazione IRCCS Istituto Nazionale dei Tumori, Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, St John of God Subiaco Hospital, European Institute of Oncology, University of Milan, Ottawa Hospital, The Christie NHS Foundation Trust, National Health Service, Università Cattolica del Sacro Cuore, Inserm, Florida Hospital Cancer Institute, Centro Oncológico de Galicia, Auckland City Hospital, Royal Brisbane and Women's Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Sidney Kimmel Comprehensive Cancer Center, HM Hospitales, University of Washington, Institut Bergonié, University of California, Los Angeles, University of Glasgow, Royal Melbourne Hospital, Clovis Oncology (United States), Royal London Hospital, University College London, London Cancer, CRUK Lung Cancer Centre of Excellence

Top 5 similar protocols

Protocol cited in 11 other protocols

Variable analysis

Dependent Variables detection not available due to copyright restrictions.
Unable to provide accurate variables.

Annotations

Annotations not available due to copyright restrictions

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!